The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study
- 1 August 2009
- journal article
- research article
- Published by Wiley in British Journal of Dermatology
- Vol. 161 (2), 313-319
- https://doi.org/10.1111/j.1365-2133.2009.09208.x
Abstract
Pemphigus vulgaris (PV) represents a potentially life-threatening autoimmune blistering disease in which IgG autoantibodies are directed against cell-cell adhesion molecules. Tumour necrosis factor (TNF)-alpha has been suggested to have a possible role in the mechanism underlying acantholysis. This comparative double-blinded study was carried out to estimate the use of both sulfasalazine (SSZ) and pentoxifylline (PTX) (low-cost anti-TNF drugs) as an adjuvant therapy for PV. The study included 64 patients with PV: 42 patients received the full treatment regimen (with SSZ and PTX) and 22 patients followed the same regimen except they received placebo instead of PTX and SSZ. Five healthy subjects were included as controls. Serum samples were taken to measure TNF-alpha levels in the control group and before starting treatment in both the patient groups and this was repeated every 2 weeks for 8 weeks; a clinical assessment was made every week for all the patients. The serum level of TNF-alpha was statistically higher in both groups of patients than in the healthy individuals. There was a statistically significant decrease in the serum levels of TNF-alpha in patients in group 1 compared with those in group 2 at 6 and 8 weeks. There was also a significant clinical improvement in patients in group 1 compared with those in group 2. The use of PTX and SSZ as adjuvant therapy in the treatment of PV induced a faster and more significant decrease in the serum level of TNF-alpha, and this decrease was associated with rapid clinical improvement.This publication has 24 references indexed in Scilit:
- Current regimen of pulse therapy for pemphigus: Minor modifications, improved resultsIndian Journal of Dermatology, Venereology and Leprology, 2008
- Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximabBritish Journal of Dermatology, 2005
- Infliximab in the management of severe pemphigus vulgarisBritish Journal of Dermatology, 2005
- Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin‐12 production and major histocompatibility complex II expressionImmunology, 2001
- The Shed Ectodomain of Collagen XVII/BP180 Is Targeted by Autoantibodies in Different Blistering Skin DiseasesThe American Journal of Pathology, 2000
- Recognition of Desmoglein 3 by Autoreactive T Cells in Pemphigus Vulgaris Patients and NormalsJournal of Investigative Dermatology, 1998
- Inhibition of human interleukin‐12 production by pentoxifyllineImmunology, 1997
- Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies.Alimentary Pharmacology & Therapeutics, 1996
- Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis ratsEuropean Journal of Immunology, 1993
- Pemphigus Antibodies Identify a Cell Surface Glycoprotein Synthesized by Human and Mouse KeratinocytesJCI Insight, 1982